A. M. Ginsberg and M. Spigelman, Challenges in tuberculosis drug research and development, Nat Med, vol.13, p.17342142, 2007.

C. Lienhardt, M. Raviglione, M. Spigelman, R. Hafner, E. Jaramillo et al., New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future, J Infect Dis, vol.205, issue.2, pp.241-250, 2012.

J. Grosset, Bacteriologic basis of short-course chemotherapy for tuberculosis, Clin Chest Med, vol.1, issue.2, p.6794976, 1980.

, World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017.

W. Fox, G. A. Ellard, and D. A. Mitchison, Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications, Int J Tuberc Lung Dis, vol.3, pp.231-279, 1999.

A. L. Cochrane, 1931-1971: a critical review, with particular reference to the medical profession, pp.1-11, 1979.

J. A. Caminero, Treatment of multidrug-resistant tuberculosis: evidence and controversies, Int J Tuberc Lung Dis, vol.10, p.16898365, 2006.

F. Mirzayev, M. Zignol, M. Danilovitz, N. Hurtado, V. Leimane et al., Abstract to the 38th World Conference on Lung Health, pp.8-12, 2000.

E. Nathanson, R. Gupta, P. Huamani, V. Leimane, A. D. Pasechnikov et al., Adverse events in the treatment of multidrug-resistant tuberculosis: Results from the DOTS-Plus initiative, Int J Tuberc Lung Dis, vol.8, p.15581210, 2004.

C. D. Mitnick, K. G. Castro, M. Harrington, L. V. Sacks, and W. Burman, Randomized trials to optimize treatment of multi-drug resistant tuberculosis, PLoS Med, vol.4, issue.11, p.292, 2007.

A. H. Diacon, A. Pym, M. Grobusch, J. M. De-los-rios, E. Gotuzzo et al., The diarylquinoline TMC207 for multidrug-resistant tuberculosis, N Engl J Med, vol.360, p.19494215, 2009.

M. T. Gler, V. Skripconoka, E. Sanchez-garavito, H. Xiao, J. L. Cabrera-rivero et al., Delamanid for multidrug-resistant pulmonary tuberculosis, N Engl J Med, vol.366, issue.23, p.22670901, 2012.

G. B. Migliori, C. Lienhardt, K. Weyer, M. J. Van-der-werf, F. Blasi et al., Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation, Eur Respir J, vol.44, issue.6, p.25435528, 2014.

. Tb-alliance, , 2019.

A. J. Nunn, I. D. Rusen, A. Van-deun, G. Torrea, P. P. Phillips et al., Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial, Trials, vol.15, p.25199531, 2009.

A. Trebucq, V. Schwoebel, Z. Kashongwe, A. Bakayoko, C. Kuaban et al., Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries, Int J Tuberc Lung Dis, vol.22, issue.1, p.29149917, 2018.

, Geneva: World Health Organisation, WHO treatment guidelines for drug-resistant tuberculosis: 2016 update (WHO/HTM/TB/2016.04), 2016.

, WHO handbook for guideline development. Geneva: World Health Organisation, 2014.

D. Food and . Administration, Guidance for Industry Exposure-Response Relationships-Study Design, Data Analysis, and Regulatory Applications, pp.800-835, 2003.

, World Health Organization, World Health Organisation: Target Regimen Profiles for TB Treatment (WHO/HTM/TB/2016.16). (Available at, 2016.

E. A. Kendall, S. Shrestha, T. Cohen, E. Nuermberger, K. E. Dooley et al., Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model, PLoS Med, vol.14, issue.1, p.28045934, 2017.

L. J. Bonnett, G. Ken-dror, G. C. Koh, and G. R. Davies, Comparing the Efficacy of Drug Regimens for Pulmonary Tuberculosis: Meta-analysis of Endpoints in Early-Phase Clinical Trials, Clin Infect Dis, vol.65, issue.1, p.28402396, 2017.

C. Lienhardt and G. Davies, Methodological issues in the design of clinical trials for the treatment of multidrug-resistant tuberculosis: challenges and opportunities, Int J Tuberc Lung Dis, vol.14, p.20392344, 2010.

G. R. Davies, P. Phillips, and T. Jaki, Adaptive clinical trials in tuberculosis: applications, challenges and solutions, Int J Tuberc Lung Dis, vol.19, issue.6, p.25946350, 2015.

C. S. Merle, K. Fielding, O. Bah-sow, M. Gninafon, M. B. Lo et al., OFLOTUB/Gatifloxacin for Tuberculosis Project. A four-month gatifloxacin-containing regimen for treating tuberculosis, N Engl J Med, vol.371, issue.17, p.25337748, 2014.

S. H. Gillespie, A. M. Crook, T. D. Mchugh, C. M. Mendel, S. K. Meredith et al., Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis, N Engl J Med, vol.371, issue.17, p.25196020, 2014.

A. Jindani, T. S. Harrison, A. J. Nunn, P. Phillips, G. J. Churchyard et al., High-dose rifapentine with moxifloxacin for pulmonary tuberculosis, N Engl J Med, vol.371, issue.17, p.25337749, 2014.

M. Imperial, P. Nahid, P. Phillips, G. R. Davies, K. Fielding et al., A Patient-Level Pooled Analysis of Treatment Shortening Regimens for Drug-Susceptible Pulmonary Tuberculosis, Nature Med, vol.24, issue.11, p.30397355, 2018.

, Report of the Technical Consultation on Advances in Clinical Trial Design for Development of New TB Treatments, Geneva: World Health Organization, vol.17, pp.14-16, 2018.

P. Phillips, C. D. Mitnick, J. D. Neaton, P. Nahid, C. Lienhardt et al., Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape, PLoS Med, vol.16, issue.3, 2019.